Is there evidence for different effects among EGFR-TKIs? Systematic review and meta-analysis of EGFR tyrosine kinase inhibitors (TKIs) versus chemotherapy as first-line treatment for patients harboring EGFR mutations.

Is there evidence for different effects among EGFR-TKIs? Systematic review and meta-analysis of EGFR tyrosine kinase inhibitors (TKIs) versus chemotherapy as first-line treatment for patients harboring EGFR mutations. Crit Rev Oncol Hematol. 2015 May; 94(2):213-27.

View in: PubMed

subject areas

Antineoplastic Combined Chemotherapy Protocols
Carcinoma, Non-Small-Cell Lung
Clinical Trials as Topic
ErbB Receptors
Humans
Lung Neoplasms
Mutation
Odds Ratio
Proportional Hazards Models
Protein Kinase Inhibitors
Treatment Outcome

authors with profiles

Marina Chiara Garassino